+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Calpain inhibitor MDL28170 modulates Abeta formation by inhibiting the formation of intermediate Abeta46 and protecting Abeta from degradation

Calpain inhibitor MDL28170 modulates Abeta formation by inhibiting the formation of intermediate Abeta46 and protecting Abeta from degradation

Faseb Journal 20(2): 331-333

The observations that three major cleavages within the transmembrane domain of APP, namely, the gamma-cleavage, -cleavage, and the newly identified zeta-cleavage, are involved in the generation of secreted Abeta40 and Abeta42 prompted us to determine how the calpain inhibitor III MDL 28170 influences these three cleavages and Abeta formation. With the use of a cell culture system, our data demonstrate that 1) at either high concentrations, or at a low range of concentrations, at early time points, MDL 28170 inhibits the formation of secreted Abeta40 and Abeta42. However, this effect is due to inhibition of the intermediate Abeta46 generation by zeta-cleavage and not due to direct inhibition of the gamma-cleavage that produces Abeta40/42 from Abeta46; 2) at low range of concentrations and at late time points, MDL 28170 causes an increase in secreted Abeta40/42 that likely results from inhibition of degradation of both the initial substrate, CTFbeta, and the final product, Abeta40/42, of gamma-secretase. These data strongly suggest that formation of Abeta46 is a key step in the gamma-secretase mediated generation of Abeta40/42 and provide a new target for the development of Abeta inhibitors. These data also suggest that calpain and related proteases, which are sensitive to MDL 28170, play an important role in the accumulation of secreted Abeta.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 048430732

Download citation: RISBibTeXText

PMID: 16354722

DOI: 10.1096/fj.05-4524fje

Related references

Calpain inhibitor MDL28170 modulates Abeta formation by inhibiting the formation of intermediate Abeta subscript 46 and protecting Abeta from degradation. FASEB journal: official ication of the Federation of American Societies for Experimental Biology 20(2): 331-333, 2006

Calpain inhibitor MDL28170 modulates Ab formation by inhibiting the formation of intermediate Ab46 and protecting Ab from degradation. The FASEB Journal 20(2): 1-3, 2006

Human anti-Abeta antibodies block Abeta fibril formation and prevent Abeta-induced neurotoxicity. Neurology 60(5 Suppl. 1): A69, 2003

The arctic mutation in the Abeta region of APP causes Alzheimers disease with increased Abeta protofibril formation and decreased Abeta peptide levels. Society for Neuroscience Abstracts 26(1-2): Abstract No -587 8, 2000

Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Molecular and Cellular Neurosciences 15(2): 183-198, 2000

P75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain. Journal of Neuroscience 31(6): 2292-2304, 2011

Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. Journal of Neuroscience 29(36): 11393-8, 2009

The relationship between Abeta-associated free radical generation and Abeta fibril formation. Society for Neuroscience Abstracts 27(1): 855, 2001

Static and dynamic AFM studies of the effect of anti-Abeta antibodies on Abeta aggregates and their formation. Biophysical Journal 86(1): 152a, 2004

A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. Journal of Biological Chemistry 282(4): 2646-2655, 2007

Salvianolic acid B inhibits Abeta fibril formation and disaggregates preformed fibrils and protects against Abeta-induced cytotoxicty. Neurochemistry International 52(4-5): 741-750, 2007

Solution NMR studies of the Abeta and Abeta peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. Journal of the American Chemical Society 126(7): 1992-2005, 2004